Literature DB >> 28063983

Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models.

Mamta Upadhyay1, Saloni Agarwal2, Pratibha Bhadauriya3, Subramaniam Ganesh4.   

Abstract

Lafora disease (LD) is an autosomal recessive form of a fatal disorder characterized by the myoclonus epilepsy, ataxia, psychosis, dementia, and dysarthria. A hallmark of LD is the presence of abnormal glycogen inclusions called Lafora bodies in the affected tissues including the neurons. LD can be caused by defects either in the laforin phosphatase coded by the EPM2A gene or in the malin E3 ubiquitin ligase coded by the NHLRC1 gene. The mouse models of LD, created by the targeted disruption of the LD genes, display several neurodegenerative changes. Prominent among them are the autophagic defects, abnormally large lysosomes, neurofibrillary tangles, amyloid beta deposits, and abnormal mitochondria. However, whether or not such neurodegenerative changes are a direct effect of the loss of laforin/malin was not unequivocally established. Here, we show that laforin- or malin-deficient neurons and fibroblasts display a significantly higher number of fragmented mitochondria. Loss of laforin or malin resulted in increased levels of the mitochondrial fission GTPase Drp1, its enhanced mitochondrial targeting, and increased intracellular calcium levels. Intriguingly, laforin and malin display opposite effects on the cellular level of parkin, an ubiquitin ligase of Drp1; loss of laforin led to reduced levels of parkin while the loss of malin resulted in increased parkin levels. Laforin and malin, however, interact with and positively regulate the activity of parkin, thus explaining the molecular basis of increased Drp1 levels in LD tissues. Our results suggest that laforin and malin are novel regulators of mitochondrial quality control pathway and that the mitochondrial dysfunction resulting from the increased Drp1 levels could underlie neuropathology in LD. Copyright Â
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epilepsy; Mitochondrial quality control; Neurodegeneration; Parkin; Post-translational modification

Mesh:

Substances:

Year:  2017        PMID: 28063983     DOI: 10.1016/j.nbd.2017.01.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  7 in total

1.  Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model.

Authors:  Belén Mollá; Miguel Heredia; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2021-01-14       Impact factor: 5.590

Review 2.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

Review 3.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

4.  Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.

Authors:  Priyanka Sinha; Bhupender Verma; Subramaniam Ganesh
Journal:  Mol Neurobiol       Date:  2020-10-22       Impact factor: 5.590

5.  Regulation of the autophagic PI3KC3 complex by laforin/malin E3-ubiquitin ligase, two proteins involved in Lafora disease.

Authors:  Pablo Sanchez-Martin; Marcos Lahuerta; Rosa Viana; Erwin Knecht; Pascual Sanz
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-11-21       Impact factor: 4.739

6.  Degradation of altered mitochondria by autophagy is impaired in Lafora disease.

Authors:  Marcos Lahuerta; Carmen Aguado; Pablo Sánchez-Martín; Pascual Sanz; Erwin Knecht
Journal:  FEBS J       Date:  2018-04-23       Impact factor: 5.542

Review 7.  E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy.

Authors:  Léa Lescouzères; Pascale Bomont
Journal:  Front Physiol       Date:  2020-10-22       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.